L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase
Rob Pieters,Stephen P. Hunger,Joachim Boos,Carmelo Rizzari,Lewis B. Silverman,André Baruchel,Nicola Goekbuget,Martin Schrappe,Ching-Hon Pui +8 more
TLDR
There is an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL and debate on the optimal formulation and dosage of these agents continues.Abstract:
Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols. Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL. Three asparaginase preparations are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG-asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase. Clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases. Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL. Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible. Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols. Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues. This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL.read more
Citations
More filters
Journal ArticleDOI
The Emerging Hallmarks of Cancer Metabolism
TL;DR: This Perspective has organized known cancer-associated metabolic changes into six hallmarks: deregulated uptake of glucose and amino acids, use of opportunistic modes of nutrient acquisition, useof glycolysis/TCA cycle intermediates for biosynthesis and NADPH production, increased demand for nitrogen, alterations in metabolite-driven gene regulation, and metabolic interactions with the microenvironment.
Journal ArticleDOI
Modulation of oxidative stress as an anticancer strategy.
TL;DR: The controversial role of ROS in tumour development and in responses to anticancer therapies is addressed, and the idea that targeting the antioxidant capacity of tumour cells can have a positive therapeutic impact is elaborate.
Journal ArticleDOI
Acute lymphoblastic leukaemia.
TL;DR: Genome-wide profiling of germline and leukaemic cell DNA has identified novel submicroscopic structural genetic changes and sequence mutations that contribute to leukaemogenesis, define new disease subtypes, affect responsiveness to treatment, and might provide novel prognostic markers and therapeutic targets for personalised medicine.
Journal ArticleDOI
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui,Jun J. Yang,Stephen P. Hunger,Rob Pieters,Martin Schrappe,Andrea Biondi,Ajay Vora,André Baruchel,Lewis B. Silverman,Kjeld Schmiegelow,Gabriele Escherich,Keizo Horibe,Yves Benoit,Shai Izraeli,Allen Eng Juh Yeoh,Der Cherng Liang,James R. Downing,William E. Evans,Mary V. Relling,Charles G. Mullighan +19 more
TL;DR: The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.
Journal ArticleDOI
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Ching-Hon Pui,Charles G. Mullighan,William E. Evans,William E. Evans,Mary V. Relling,Mary V. Relling +5 more
TL;DR: Specific areas of research are discussed that promise to further refine current treatment and to improve the cure rate and quality of life of the patients.
References
More filters
Journal ArticleDOI
Acute lymphoblastic leukaemia
TL;DR: Advances in understanding of the pathobiology of acute lymphoblastic leukaemia, fuelled by emerging molecular technologies, suggest that drugs specifically targeting the genetic defects of leukaemic cells could revolutionise management of this disease.
Journal ArticleDOI
Treating childhood acute lymphoblastic leukemia without cranial irradiation.
Ching-Hon Pui,Dario Campana,Deqing Pei,W. Paul Bowman,John T. Sandlund,Sue C. Kaste,Raul C. Ribeiro,Jeffrey E. Rubnitz,Susana C. Raimondi,Mihaela Onciu,Elaine Coustan-Smith,Larry E. Kun,Sima Jeha,Cheng Cheng,Scott C. Howard,Vickey Simmons,Amy Bayles,Monika L. Metzger,James M. Boyett,Wing Leung,Rupert Handgretinger,James R. Downing,William E. Evans,Mary V. Relling +23 more
TL;DR: With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL.
Journal ArticleDOI
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
Lewis B. Silverman,Richard D. Gelber,Virginia Dalton,Barbara L. Asselin,Ronald D. Barr,Luis A. Clavell,Craig A. Hurwitz,Albert Moghrabi,Yvan Samson,Marshall A. Schorin,Steven Arkin,Lieven Declerck,Harvey J. Cohen,Stephen E. Sallan +13 more
TL;DR: Treatment on Protocol 91-01 significantly improved the outcome of children with ALL, perhaps due to the prolonged asparaginase intensification and/or the use of dexamethasone, may be due, in part, to increased intolerance of intensive therapy.
Acute Lymphoblastic Leukaemia
TL;DR: This chapter is dedicated to the preparation of ALL samples for cytogenetic and FISH analysis, with emphasis on the modifications to standard protocols which may be used to improve their quality.
Journal ArticleDOI
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Jonathan K. Armstrong,Georg Hempel,Susanne Koling,Linda S. Chan,Timothy C. Fisher,Herbert J. Meiselman,George Garratty +6 more
TL;DR: The objective of the study was to determine whether anti‐PEG was associated with rapid clearance PEG‐ASNase, and if so, how prevalent it was in healthy blood donors.
Related Papers (5)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a children's Cancer Group Study
Vassilios I. Avramis,Susan Sencer,Antonia Periclou,Harland N. Sather,Bruce Bostrom,Lewis J. Cohen,Alice G. Ettinger,Lawrence J. Ettinger,Janet Franklin,Paul S. Gaynon,Joanne M. Hilden,Beverly J. Lange,Fataneh Majlessipour,Pracad Mathew,Michael N. Needle,Joseph P. Neglia,Gregory H. Reaman,John S. Holcenberg +17 more